Literature DB >> 2990751

Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas.

J H Edmonson, H J Long, R L Richardson, E T Creagan, S J Green.   

Abstract

In all 63 patients were treated monthly with a combination of mitomycin, doxorubicin, and cisplatin, and 27 (43%) experienced objective regression of their advanced sarcomas during a 3-month trial. The observed regression rate is numerically higher than any previously observed at our institution.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2990751     DOI： 10.1007/bf00257535

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  7 in total

1.  Mitomycin C.

Authors:  A E EVANS
Journal:  Cancer Chemother Rep       Date:  1961-10

2.  A comparative clinical trial evaluating the combination of adriamycin, DTIC, and vincristine, the combination of actinomycin D, cyclophosphamide, and vincristine, and a single agent, methyl-CCNU, in advanced sarcomas.

Authors:  E T Creagan; R G Hahn; D L Ahmann; J H Edmonson; H F Bisel; R T Eagan
Journal:  Cancer Treat Rep       Date:  1976-09

3.  Differing response rates and survival between squamous and non-squamous non-small cell lung cancer. Comparison of CAP versus MAP.

Authors:  R T Eagan; S Frytak; E T Creagan; R L Richardson; D T Coles; J R Jett
Journal:  Am J Clin Oncol       Date:  1986-06       Impact factor: 2.339

4.  A preliminary study of cyclophosphamide (NSC-26271), adriamycin (NSC-123127), imidazole carboxamide (NSC-45388), and actinomycin D (NSC-3053) with or without MER-BCG in patients with advanced sarcomas.

Authors:  E T Creagan; J H Edmonson; R G Hahn; D L Ahmann; H F Bisel; R T Eagan
Journal:  Med Pediatr Oncol       Date:  1978

5.  The results of surgical treatment combined with intra-arterial infusion of anti-cancer agents in osteosarcoma.

Authors:  Y AKAHOSHI; S Takeuchi; S H Chen; T Nishimoto; A Kikuike; H Yonezawa; T Yamamuro
Journal:  Clin Orthop Relat Res       Date:  1976-10       Impact factor: 4.176

6.  Cyclophosphamide, doxorubicin, and cisplatin combined in the treatment of advanced sarcomas.

Authors:  J H Edmonson; R G Hahn; A J Schutt; H F Bisel; J N Ingle
Journal:  Med Pediatr Oncol       Date:  1983

7.  Failure of bleomycin to improve the therapeutic effects of a combination of cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced sarcomas.

Authors:  J H Edmonson; E T Creagan; L K Kvols; R L Richardson; J Rubin; S J Green
Journal:  Med Pediatr Oncol       Date:  1984
  7 in total
  4 in total

1.  Synovial sarcoma of the esophagus: report of a case.

Authors:  S Habu; E Okamoto; A Toyosaka; Y Nakai; M Takeuchi
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

Review 2.  Chemotherapy for metastatic soft tissue sarcomas--another full circle?

Authors:  V H Bramwell
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

3.  Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation.

Authors:  Flemming Brandt Sorensen; Kenneth Jensen; Michael Vaeth; Henrik Hager; Anette Mariane Daa Funder; Akmal Safwat; Johnny Keller; Mariann Christensen
Journal:  Sarcoma       Date:  2009-02-25

4.  A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS).

Authors:  Haralabos P Kalofonos; Charalabos Kourousis; Michalis V Karamouzis; Gregoris Iconomou; Ekaterini Tsiata; Fotis Tzorzidis; Panagiotis Megas; Elias Lambiris; Vasilios Georgoulias
Journal:  Sarcoma       Date:  2004
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.